Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression -225% Improvement Relative Risk c19early.org/mf Gao et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 110 patients in China (January - March 2020) Higher progression with metformin (p=0.045) Gao et al., Clinical and Translational Science, doi:10.1111/cts.12897 Favors metformin Favors control
Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A Preliminary Retrospective Report
Gao et al., Clinical and Translational Science, doi:10.1111/cts.12897
Gao et al., Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A Preliminary Retrospective Report, Clinical and Translational Science, doi:10.1111/cts.12897
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 110 hospitalized COVID-19 patients with diabetes in China, showing increased risk of severity with metformin.
risk of progression, 225.0% higher, RR 3.25, p = 0.045, treatment 16 of 56 (28.6%), control 4 of 54 (7.4%), odds ratio converted to relative risk, progression to life threatening complications.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gao et al., 19 Oct 2020, retrospective, China, peer-reviewed, 7 authors, study period 31 January, 2020 - 20 March, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Citation: Clin. Transl. Sci (2020) 13, 1055–1059; doi:10.1111/cts.12897 BRIEF REPORT Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A Preliminary Retrospective Report Yongchao Gao1,2,3,4, Tao Liu5, Weijun Zhong1,2,3,4, Rong Liu1,2,3,4, Honghao Zhou1,2,3,4, Weihua Huang1,2,3,4,* and Wei Zhang1,2,3,4,* The current outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread across the world. No specific antiviral agents have been adequately evidenced for the treatment of coronavirus disease 2019 (COVID19). Although metformin has been recommended as a host-directed therapy for COVID-19, there are some opposite views. The effects of metformin on the disease severity of patients with COVID-19 with diabetes during hospitalization remains unclear. This study aimed to determine the effect of metformin on disease severity. We enrolled 110 hospitalized patients with COVID-19 with diabetes prescribed either metformin or non-metformin hypoglycemic treatment for a case-control study. The primary outcome was the occurrence of life-threatening complications. There were no differences between the two groups in age, sex, comorbidities, and clinical severity at admission. Blood glucose and lactate dehydrogenase levels of the metformin group were higher than those of the non-metformin group at admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. Strikingly, the percentage of patients who experienced life-threatening complications was significantly higher in the metformin group (28.6% (16/56) vs. 7.4% (4/54), P = 0.004). Antidiabetic therapy with metformin was associated with a higher risk of disease progression in patients with COVID-19 with diabetes during hospitalization (adjusted odds ratio = 3.964, 95% confidence interval 1.034–15.194, P = 0.045). This retrospective analysis suggested a potential safety signal for metformin, the use of which was associated with a higher risk of severe COVID-19. We propose that metformin withdrawal in patients with COVID-19 be considered to prevent disease progression. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ✔ Diabetes is one of the most important comorbidities of coronavirus disease 2019 (COVID-19) associated with higher mortality. Metformin has been proposed to be a candidate for host-directed treatment for COVID-19. However, recent studies have argued that the risks of metformin in patients with COVID-19 and diabetes need to be considered. WHAT QUESTION DID THIS STUDY ADDRESS? ✔ We aimed to assess the association between metformin and life-threatening complications by conducting a comparison on patients with COVID-19 with diabetes between metformin users and nonusers. WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? ✔ Among those patients with COVID-19 with diabetes, more severe cases were found in metformin users than in non-metformin cases (28.6% vs. 7.4%, P = 0.004). Antidiabetic therapy with metformin was associated with a higher risk of severe illness (adjusted odds ratio 3.964, 95% confidence interval 1.034–15.194). HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? ✔ This study highlighted a potential safety signal for metformin, the use of which was associated with a higher risk of severe COVID-19. Thus, we propose that metformin withdrawal in patients with COVID-19 be considered to prevent disease progression. The current outbreak of..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit